A b s t r a c t

We studied vascular endothelial growth factor (VEGF) expression in bone marrow sections obtained from 3 healthy donors and 41 patients with acute myeloid leukemia (AML) of various French-AmericanBritish (FAB) subtypes by immunohistochemical analysis using an anti-VEGF antibody. In normal bone marrow, the anti-VEGF antibody reacted with myeloid progenitor cells and megakaryocytes but not with erythroid cells or mature granulocytic cells. High levels of VEGF were found in the bone marrow in patients with AML-M1, -M2, -M3, -M4, -M4Eo, and -M5. In these leukemias, the vast majority of myeloblasts (>90%) expressed VEGF. By contrast, in AML-M0, the percentage of VEGF-positive blasts was lower in most cases (median, 42%), and if at all detectable, these blast cells contained only trace amounts of VEGF. In AML-M3 and -M4Eo, maturing granulocytes failed to express VEGF similar to granulocytes in normal bone marrow. In AML-M6, myeloblasts exhibited VEGF, whereas erythroid cells did not. In AML-M7, blast cells and megakaryocytes were identified as major sources of VEGF. In summary, VEGF expression in the bone marrow is restricted to certain stages of differentiation and maturation of myeloid cells and correlates with the FAB category.
Acute myeloid leukemia (AML) is characterized by clonal proliferation of immature myeloid (progenitor) cells without substantial maturation. 1, 2 The prognosis and clinical picture in AML varies depending on the genes that underwent deregulation, cell types involved, and the specific biologic properties of the clone. [3] [4] [5] [6] [7] Traditionally, the AMLs have been classified according to the proposal of the FrenchAmerican-British (FAB) Cooperative Study Group. [8] [9] [10] [11] More recently, this proposal has been extended and modified by guidelines provided in the World Health Organization classification of tumors of hematopoietic and lymphoid tissues. 12, 13 Recent data suggest that vascular endothelial growth factor (VEGF) is overexpressed in patients with AML and has a potential role in the pathogenesis of myeloid leukemias. [14] [15] [16] [17] [18] [19] In fact, VEGF has been implicated as an essential mediator of leukemia-dependent angiogenesis. [14] [15] [16] [17] [18] [19] In addition, this cytokine has been described as an autocrine and paracrine growth regulator of AML cells. [18] [19] [20] Indeed, VEGF is produced and secreted in AML blasts in a constitutive manner. [14] [15] [16] [17] [18] [19] Correspondingly, increased levels of VEGF are detectable in serum samples of patients with AML. [14] [15] [16] [17] [18] [19] However, little is known about VEGF expression in various subtypes of AML and about the exact distribution of this cytokine in the cellular compartments of the normal and leukemic bone marrow.
Recently, a VEGF-staining protocol suitable for detection of the cytokine in paraffin-embedded bone marrow biopsy sections has been established. 21 In the present study, we applied this protocol to a cohort of 41 patients with AML to study expression and distribution of VEGF in the bone marrow in various subtypes of AML. (15) with biotinylated goat antirabbit IgG for 30 minutes, washed, and exposed to biotin-peroxidase complex. 3-Amino-9-ethyl carbazole was used as the chromogen. Slides were counterstained in Mayer hemalaun.
Short-Term Culture and Measurement of VEGF Secreted From AML Blasts
In 4 patients with AML, bone marrow aspirates were diluted in buffer and layered over Ficoll to isolate myeloblasts. After isolation, AML blasts were cultured in RPMI 1640 medium (PAA Laboratories, Linz, Austria) supplemented with 10% fetal calf serum (PAA Laboratories) in 5% carbon dioxide at 37°C for 35 days. During the culture period, cellfree supernatants and intact cells were recovered every 4 or 5 days. Lysates of cultured cells were prepared by centrifugation and freeze-thawing. The levels of VEGF were determined by a specific enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN) with a detection limit of 5 pg/mL of VEGF.
Northern Blot Analysis
Total RNA was extracted from myeloid progenitors of 3 patients with AML and 1 patient with chronic myeloid leukemia (CML) using Trizol (Gibco BRL, Carlsbad, CA) according to the manufacturer's instructions. CML cells were preincubated with control medium or rapamycin (20 nmol/L; Calbiochem, San Diego, CA) at 37°C for 24 hours as reported. 22 Northern blot analysis was performed as described. 22 In brief, 20 µg of RNA were size-fractionated on 1.0% formaldehyde-agarose gels, transferred to synthetic membranes (Hybond N, Amersham, Aylesbury, England) as described by Chomczynski, 23 and cross-linked by UV irradiation. Then, membranes were prehybridized. Hybridization was performed with a phosphorus 32-labeled complementary DNA (cDNA) probe specific for VEGF as reported. 22 Labeling was performed using a Megaprime kit (Hybond N, Amersham). Blots were washed in 2× standard saline citrate (SSC; 1× SSC = 150 mmol/L of sodium chloride and 15 mmol/L of sodium citrate, pH 7.0) and 0.1% sodium dodecyl sulfate (SDS) at room temperature for 1 hour and thereafter in 0.2× SSC with 0.1% SDS at 42°C for 30 minutes and at 62°C for another 30 minutes. Bound radioactivity was visualized by exposure to Biomax MS film (Kodak, Rochester, NY) at -80°C using intensifying screens (Kodak).
Results
Expression and Distribution of VEGF in Normal Bone Marrow
In normal bone marrow samples, the anti-VEGF antibody reacted with immature myeloid progenitor cells (blasts), promyelocytes, myelocytes, and megakaryocytes ❚Image 1❚. Plasma cells also were labeled by the anti-VEGF antibody. By contrast, mature granulocytic cells did not express measurable amounts of VEGF, and erythroid (progenitor) cells were consistently negative for VEGF (Image 1). Identical staining results were obtained in the 3 normal bone marrow samples analyzed. ❚Table 2❚ shows a summary of VEGF staining results obtained in normal bone marrow samples.
❚ ❚Image 1❚ ❚ Expression of vascular endothelial growth factor (VEGF) in normal bone marrow. Immunohistochemical staining with anti-VEGF antibody was carried out as described in the text. As visible, bone marrow megakaryocytes and immature myeloid cells were found to react with the VEGF antibody. Lower levels of VEGF were found in maturing granulocytic cells, whereas erythroid cells did not react with the anti-VEGF antibody (×150). 
Immunohistochemical Detection of VEGF in AML Blasts
VEGF was detectable in bone marrow sections in all patients with AML. To confirm specificity of staining for VEGF in bone marrow sections in AML, experiments using a VEGF-blocking peptide were performed. In these experiments, preincubation of the antibody with the blocking peptide resulted in a negative staining result, suggesting that the antibody applied indeed recognized the VEGF protein (not shown). The intensity of staining and the percentage of positive cells varied among patients with AML, especially among FAB categories. Measurable amounts of VEGF were detectable in the bone marrow in patients with the AML subtypes M1, M2, M3, M4, M4Eo, M5, M6, and M7 ❚Image 2❚ and ❚Table 3❚ (Table 2) . Thus, in all FAB subtypes except AML-M0, the vast majority of the myeloblasts (>90%) appeared to express VEGF (Image 2, Tables 2 and 3) . By contrast, the maturing granulocytic cells contained only trace amounts of VEGF or failed to express the cytokine. Likewise, in AML-M3, blast cells were positive for VEGF, whereas VEGF was not detectable in mature granulocytic cells (Image 2C). Similarly, in AML-M4Eo, the neoplastic eosinophils did not react with the anti-VEGF antibody (Image 2E). In AML-M6, myeloblasts also were positive for VEGF, whereas most cells in the erythroid compartment did not express VEGF (Image 2G). In all FAB categories, including M7, megakaryocytes were positive for VEGF (Image 2H). In AML-M0, the percentage of VEGF-positive blast cells was lower, and the percentage of VEGF-negative blasts was clearly higher in most cases compared with samples in the other FAB subtypes examined. Thus, the median percentage of VEGF-negative blast cells amounted to 58% in AML-M0 but was less than 10% in the other FAB subtypes (Table 3) . Moreover, if at all detectable in blast cells in AML-M0, the intensity of staining for VEGF was weak (Table 3 , Image 2A). In 1 case of AML-M0, however, the majority of the myeloblasts expressed detectable VEGF, contrasting with the other M0 cases. In this particular case, we also were able to detect substantial numbers of megakaryocytes, and a thorough reexamination of this case revealed expression of factor VIII-related antigen (but not CD61) in a subset of myeloblasts. Based on expression of VEGF and factor VIII-related antigen in some blasts, we believe that this particular case probably represented an extremely immature form of megakaryoblastic leukemia despite lack of CD61 expression.
Detection of VEGF in Supernatants of Isolated AML Blasts
To confirm production of the VEGF protein in AML cells, culture experiments were conducted using bone marrow-derived AML blasts. During a culture period of 35 days, the levels of VEGF in the cell-free supernatants increased substantially in all 4 cases examined ❚Figure 1❚, whereas cellular levels of VEGF in AML blasts remained low and did not change during culture (not shown). These data strongly suggest that AML blasts actively produce and secrete the VEGF protein in vitro.
Expression of VEGF Messenger RNA in AML Cells
To provide further evidence for production of VEGF in AML blasts, Northern blot experiments were performed in 3 cases of AML using isolated blast cells and a cDNA probe specific for human VEGF. In these experiments, unstimulated AML blasts were found to express VEGF messenger RNA (mRNA) ❚Image 3❚. These data provide further evidence that AML blasts synthesize VEGF in a constitutive manner. The specificity of the VEGF probe was controlled by probing mRNA from leukemic CML cells that had been incubated in control medium or rapamycin. As reported previously, 22 CML cells expressed VEGF mRNA in a constitutive manner, and exposure to rapamycin resulted in a substantial decrease in expression of VEGF mRNA compared with unstimulated cells (Image 3).
Discussion
Recent data suggest that VEGF is an important pathogenetic factor in myeloid leukemias. [14] [15] [16] [17] [18] [19] [20] In particular, VEGF has been described as a mediator of leukemia-dependent angiogenesis and as an autocrine growth regulator of AML cells. [18] [19] [20] However, so far, little is known about the distribution of VEGF in normal and leukemic bone marrow and expression of VEGF in the various subtypes of AML. Recently, a VEGF staining protocol that can be used on bone marrow sections has been established. 21 By using this protocol, we were able to study VEGF expression in bone marrow cells in various subtypes of AML. The results of our study show that VEGF is expressed as a lineage-related and cell-specific marker antigen in normal bone marrow and in bone marrow samples in patients with AML.
In the normal bone marrow, VEGF was detected in megakaryocytes and myeloid progenitor cells, whereas mature granulocytic cells and erythroid cells did not express detectable amounts of VEGF. Corresponding results were obtained in the majority of samples from patients with AML. In fact, in all patients with FAB AML M1 through M7, the vast majority of myeloblasts, as well as the megakaryocytes, were positive for VEGF.
An unexpected finding was that in most cases (5/6) of AML-M0, only a subset of blast cells expressed VEGF. Moreover, in these cases, blast cells (if at all immunoreactive for VEGF) expressed only trace amounts of the cytokine. One explanation for this finding would be that VEGF is not expressed in the earliest phases of AML stem cell development but only later during progenitor cell differentiation. Similarly, myeloperoxidase is not expressed at the "AML-M0 level" of stem cell differentiation. 11 On the other hand, recent data suggest that normal murine hematopoietic stem cells express VEGF and use this cytokine as an autocrine growth factor similar to AML blasts. 24 An alternative explanation for the low levels of VEGF detected in M0 blast cells would be that VEGF is degraded or released at a higher rate in blast cells in AML-M0 compared with other leukemias. In 1 patient with AML-M0, however, the majority of the myeloblasts (>90%) expressed VEGF, contrasting with the poor VEGF staining result obtained in the other cases of AML-M0. This observation prompted us to reexamine this particular (VEGF-positive) case of AML-M0 in detail. Respective examinations revealed that a small subset of myeloblasts expressed factor VIII-related antigen, albeit lacking CD61 expression. In addition, this case revealed substantial numbers of megakaryocytes in the bone marrow. Based on these observations, this particular case was discussed as possibly being an extremely immature variant of a (pre)megakaryoblastic leukemia (although still classified as AML-M0 according to FAB criteria 10, 11 ).
As in normal bone marrow, maturing granulocytic cells in AML were only weakly reactive for VEGF or were completely negative for VEGF. Especially in AML-M3 (mature neutrophils) and AML-M4Eo (eosinophils), granulocytes were negative for VEGF. Thus, VEGF seems to be a differentiation-associated molecule expressed primarily at an immature stage of granulomonocytic development. These data point to an important role of VEGF in early myelopoiesis and a less important role in advanced stages of myeloid differentiation. However, this may hold true only for granulomonocytic cells, whereas all cells in the megakaryocytic differentiation pathway (platelets, megakaryocytes, megakaryoblasts) express VEGF. 25, 26 In fact, platelets are considered an important source of VEGF in health and disease. 25, 26 In line with the well-known expression of VEGF in megakaryopoietic cells, we also were able to detect VEGF in immature megakaryocytes in AML-M7. An interesting observation was that erythroid cells lack VEGF. In fact, in normal bone marrow samples and in bone marrow samples from patients with AML-M6, erythroid cells were consistently negative for VEGF. Recent data suggest that VEGF plays a role as an autocrine growth regulator for normal and leukemic myeloid cells. [14] [15] [16] [17] [18] [19] [20] Especially in AML, VEGF has been described as an autocrine growth factor. [18] [19] [20] The notion that myeloblasts in most patients with AML express VEGF in a constitutive manner would support this hypothesis. In addition, we were able to show that AML blasts secrete VEGF into the supernatant in a factor-independent manner. It also is noteworthy in this regard that AML blasts have been described as expressing receptors for VEGF. 17, 19, 20 All these data point to an important role for VEGF as an autocrine growth factor in AML.
Another important aspect is that VEGF is a well-known angiogenic molecule. [27] [28] [29] [30] In fact, VEGF has been implicated in leukemia-associated angiogenesis. Since the bone marrow in AML exhibits increased angiogenesis and microvessel density, [14] [15] [16] [17] [18] [19] [20] [27] [28] [29] [30] it seems likely that blast cell-derived VEGF has a role in the microvessel formation in AML. On the other hand, VEGF is not the only angiogenic factor known to be produced and released in myeloid cells. In fact, apart from VEGF, other cytokines such as fibroblast growth factors, interleukin-8, hepatocyte growth factor, tryptases, and the angiopoietins may be produced by leukemic cells and may act as angiogenic factors in the leukemic bone marrow. 29, 30 Some of these cytokines may indeed contribute to increased vessel formation in the bone marrow in patients with AML. 29, 30 Recent studies have shown that the levels of VEGF correlate with the prognosis in patients with AML. 16 In the present study, however, we did not measure serum VEGF levels in patients with AML, and no major differences in staining of bone marrow blast cells were found among cases in various FAB categories except AML-M0. Moreover, it seems impossible to predict the total levels of VEGF from the VEGF staining results of bone marrow samples since the total amount of VEGF also is dependent on the total burden of leukemic cells and the rate of production and release of the cytokine in AML blasts.
In summary, VEGF is expressed in blast cells, immature granulomonocytic cells, and megakaryocytes in normal bone marrow and in the bone marrow of patients with AML. Given its cell type-specific and maturation-associated expression in myeloid cells, VEGF may be regarded as a useful immunohistochemical marker in AML. ❚ ❚Image 3❚ ❚ Expression of vascular endothelial growth factor (VEGF) messenger RNA (mRNA) by acute myeloid leukemia (AML) blasts. Top, Blast cells were isolated from 3 patients with AML and subjected to Northern blot analysis. As shown, AML blasts expressed VEGF mRNA in a constitutive manner in all samples examined. Bottom, To confirm specificity of the VEGF probe, Northern blot analysis also was performed using chronic myeloid leukemia (CML) cells exposed to control medium or rapamycin. Corresponding to previous data, 22 CML cells expressed VEGF mRNA, and rapamycin produced significant inhibition of VEGF mRNA expression in these cells. rRNA, ribosomal RNA.
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